when antibody readings were obtained 28 days after the second vaccination dose. Antibody levels at 45 weeks intervals between the first and second vaccine doses were four times higher than antibody levels at 12 weeks intervals, indicating that the spacing between the first and second doses of vaccine was four times higher. Longer does not cause negative effects. But it can stimulate the immune level to be higher.
In addition, vaccination against COVID-19 of AstraZeneca A third dose, 6 months after the second dose, can induce a 6-fold increase in antibody levels and promote the activity of in vivo T lymphocytes. It also found that the vaccine against COVID-19 of Astrazenegados III Has a higher protection against coronavirus Alpha strain (B.1.1.7 or Kent strain), Beta strain (B.1.351 or South Africa strain) and Delta strain (B.1.617. 2 or Indian species)
The vaccination against COVID-19 Of the second, more spaced astrasenegados and the third doses, the incidence of adverse reactions was lower than the first dose of vaccination.
For this trial in the COV001 and COV002 groups, volunteers aged 18-55 years were vaccinated against COVID-19. of AstraZeneca Either one or two doses were given.
The COV001 cohort study based on Phase I and II studies in a randomized, unilateral, blindfolded control group. To assess the safety of the AZD1222 vaccine. the ability to build immunity and effectiveness There were 1,077 volunteers from five trial centers in the UK. They are in the age group of 18-55 years who are in good health. A randomized group of subjects received one or two doses of AZD1222 vaccine. which has a viral particle content of 5×1010 or one dose of MenACWY meningococcal vaccine.
The volunteers’ blood samples were taken for examination at different times. From the first day, day 28, day 184 and day 364 to check safety and immunization. In addition, subjects who enrolled in the Phase I trial and were in the two-dose vaccination group were monitored on Day 3, Day 7, Day 14, and Day 28 after each dose of vaccine.
The COV002 cohort study is a Phase II and III cohort study in a randomized, unilateral, multicenter multicenter randomized controlled trial evaluating the safety of the AZD1222 vaccine. Effectiveness and Immunity There were 12,390 volunteers in the UK aged 18 years and over, consisting of healthy people and people with underlying disease, whose symptoms were still under control. This is a group of people who are more at risk of getting SARS-C0V-2 virus than the general public. A randomized group of subjects received one or two doses of AZD1222 vaccine. from an intramuscular injection with a half-dose equivalent of viral particles The meningococcal meningococcal vaccine (~2.5 x 1010 viral load) or full dose (~5 x 1010 viral load) was compared with the MenACWY meningococcal vaccine group.
Volunteers’ blood samples were taken for testing at various intervals one year after vaccination to determine safety and immunization. Volunteers who show symptoms similar to infection will be tested for COVID-19 via PCR technique. To test for infection and collect information on the effectiveness of the vaccine.